Related Experiment Videos
Expanding indications for defibrillators after myocardial infarction: risk stratification and cost effectiveness
Vidal Essebag1, Mark J Eisenberg
1Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Cardiac Electrophysiology Review
|May 27, 2003
Insights
Implantable cardioverter-defibrillators (ICDs) are recommended for post-myocardial infarction (MI) patients with low ejection fraction (LVEF). However, cost-effectiveness varies by patient subgroup, necessitating better risk stratification for optimal resource allocation.
Area of Science:
- Cardiology
- Medical Devices
- Health Economics
Background:
- New guidelines recommend implantable cardiac defibrillators (ICDs) for patients post-myocardial infarction (MI) with left ventricular ejection fraction (LVEF) ≤30%, based on the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II).
- Millions of patients meet these criteria, raising concerns about substantial healthcare costs.
- The benefits and cost-effectiveness of ICD therapy require further investigation within specific patient subgroups.
Purpose of the Study:
- To analyze the implications of the MADIT II trial findings for clinical practice and healthcare resource allocation.
- To evaluate the potential benefits and cost-effectiveness of ICD therapy across different patient subgroups.
- To identify the need for improved risk stratification strategies for selecting patients who will benefit most from ICD implantation.
Main Methods:
- Review and interpretation of the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) results.
- Analysis of potential variations in ICD therapy benefits across patient subgroups.
- Consideration of alternative therapies, such as amiodarone and beta-blockers, in comparison to ICDs.
Main Results:
- Subgroups with QRS duration >0.12 seconds or LVEF ≤25% appear to gain the greatest benefit from ICD therapy.
- The cost-effectiveness of ICDs is dependent on the magnitude of benefit, which varies across patient risk levels.
- Optimal medical therapy, including amiodarone and beta-blockers, needs comparative evaluation against ICD therapy.
Conclusions:
- Better risk stratification tools are essential to identify patients most likely to benefit from ICDs.
- Prioritizing healthcare resources requires understanding which patient subsets gain the most from ICD therapy.
- Ongoing studies are crucial to determine the relative effectiveness of ICDs versus optimal medical therapy.
Abstract:
Practice guidelines have expanded to include a new Class IIa recommendation for implantable cardiac defibrillator (ICD) use in patients post-myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) 0.12 seconds or LVEF